Waters introduces new TQ-S and G2 QTof mass spectrometers for Xevo MS platform

NewsGuard 100/100 Score

Waters Corporation (NYSE: WAT) introduced today two new mass spectrometers for its Xevo MS platform – the Xevo TQ-S and Xevo G2 QTof – that bring a step change in performance to benchtop mass spectrometry. The product introductions were made at the 58th annual meeting of the American Society for Mass Spectrometry (ASMS).

The Xevo TQ-S and Xevo G2 QTof are the newest members of the Xevo family of benchtop mass spectrometers first introduced in 2008 and are the most powerful mass spectrometers in their class. Combined with Waters® ACQUITY® UltraPerformance LC® (UPLC®) Systems these mass spectrometers offer scientists an unequalled combination of separations power with highest levels of sensitivity whether for compound identification, quantification, and screening, or for extracting the most information from the smallest sample volumes all in a single analysis.

Said Brian Smith, V.P. Mass Spectrometry Operations, Waters Division, "With today's announcements, Waters has firmly established its leadership position in high-performance mass spectrometry. The new features and innovations scientists will find in our new Xevo mass spectrometers, more than anything else, are intended to deliver results. As they have told us time and again, that's what really counts."

At a press conference today, Waters global Vice President of Worldwide Marketing, Dr. Rohit Khanna, remarked, "Our customers have told us they want high-quality, high-impact results faster, and with less effort. These new additions to our Xevo family of mass spectrometers mean we can deliver applications-specific UPLC/MS/MS systems that can help them achieve their scientific and business objectives and put answers to complex challenges within easy reach."

Waters expects to begin shipping the Xevo G2 QTof system in June and the Xevo TQ-S system in September.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study links endocrine-disrupting chemical exposure to poorer sleep and vitamin D deficiency